Till sidans topp

Sidansvarig: Webbredaktion
Sidan uppdaterades: 2012-09-11 15:12

Tipsa en vän
Utskriftsversion

Promising Prospects for S… - Göteborgs universitet Till startsida
Webbkarta
Till innehåll Läs mer om hur kakor används på gu.se

Promising Prospects for Sc-44-/Sc-47-Based Theragnostics: Application of Sc-47 for Radionuclide Tumor Therapy in Mice

Artikel i vetenskaplig tidskrift
Författare C. Muller
M. Bunka
S. Haller
U. Koster
V. Groehn
Peter Bernhardt
N. van der Meulen
A. Turler
R. Schibli
Publicerad i Journal of Nuclear Medicine
Volym 55
Nummer/häfte 10
Sidor 1658-1664
ISSN 0161-5505
Publiceringsår 2014
Publicerad vid Institutionen för kliniska vetenskaper, Avdelningen för radiofysik
Sidor 1658-1664
Språk en
Länkar dx.doi.org/10.2967/jnumed.114.14161...
Ämnesord Sc-47, radionuclide therapy, SPECT, folate receptor, folic acid, CARRIER-ADDED SC-47, IN-VIVO, CONJUGATE, PET, RADIOPHARMACEUTICALS, RADIOIMMUNOTHERAPY, TISSUES, LU-177, TB-161, ALPHA, Radiology, Nuclear Medicine & Medical Imaging
Ämneskategorier Medicinska grundvetenskaper

Sammanfattning

In recent years, Sc-47 has attracted attention because of its favorable decay characteristics (half-life, 3.35 d; average energy, 162 key; Ey, 159 key) for therapeutic application and for SPECT imaging. The aim of the present study was to investigate the suitability of Sc-47 for radionuclide therapy in a preclinical setting. For this purpose a novel DOTA-folate conjugate (cm10) with an albumin-binding entity was used. Methods: Sc-47 was produced via the Ca-46(n,gamma)Ca-47 -> Sc beta-47 nuclear reaction at the high-flux reactor at the Institut Laue-Langevin. Separation of the Sc-47 from the target material was performed by a semi-automated process using extraction chromatography and cation exchange chromatography. Sc-47-labeled cm10 was tested on folate receptor-positive KB tumor cells in vitro. Biodistribution and SPECT imaging experiments were performed in KB tumor-bearing mice. Radionuclide therapy was conducted with two groups of mice, which received either Sc-47-cm10 (10 MBq) or only saline. Tumor growth and survival time were compared between the two groups of mice. Results: Irradiation of Ca-46 resulted in approximately 1.8 GBq of Ca-47, which subsequently decayed to Sc-47. Separation of Sc-47 from Ca-47 was obtained with 80% yield in only 10 min. The Sc-47 was then available in a small volume (-500 pL) of an ammonium acetate/HCI (pH 4.5) solution suitable for direct radiolabeling. Sc-47-cm10 was prepared with a radiochemical yield of more than 96% at a specific activity of up to 13 MBq/nmol. In vitro 475ccm10 showed folate receptor-specific binding and uptake into KB tumor cells. In vivo SPECT/CT images allowed the visualization of accumulated radioactivity in KB tumors and in the kidneys. The therapy study showed a significantly delayed tumor growth in mice, which received Sc-47-cm10 (10 MBq, 10 Gy) resulting in a more than 50% increase in survival time, compared with untreated control mice. Conclusion: With this study, we demonstrated the suitability of using Sc-47 for therapeutic purposes. On the basis of our recent results obtained with Sc-44-folate, the present work confirms the applicability of Sc-44/Sc-47 as an excellent matched pair of nuclides for PET imaging and radionuclide therapy.

Sidansvarig: Webbredaktion|Sidan uppdaterades: 2012-09-11
Dela:

På Göteborgs universitet använder vi kakor (cookies) för att webbplatsen ska fungera på ett bra sätt för dig. Genom att surfa vidare godkänner du att vi använder kakor.  Vad är kakor?

Denna text är utskriven från följande webbsida:
http://www.gu.se/forskning/publikation/?publicationId=205504
Utskriftsdatum: 2020-01-23